Orexo to Present New Strategy and AmorphOX Pipeline at March R&D Day

Orexo AB ( (SE:ORX) ) has shared an announcement.

Orexo AB will host an R&D Day for investors, analysts and media at the Royal Swedish Academy of Engineering Sciences in Stockholm on March 24, 2026, where CEO Nikolaj Sørensen and the management team will outline the company’s updated strategic direction and priorities following the divestment of Zubsolv in the U.S. market. The event will also spotlight the science and commercial potential of its AmorphOX drug‑delivery platform, provide updates on ongoing development programs and target markets, and feature a discussion on the growing use of alpha‑2 agonists such as xylazine and their implications for overdose reversal, underlining the strategic importance of Orexo’s OX390 program for addressing emerging unmet needs in addiction and overdose care.

The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK28.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.

More about Orexo AB

Orexo AB is a Swedish pharmaceutical company focused on advanced treatments for severe diseases and life‑saving rescue medications, built around its proprietary AmorphOX drug‑delivery technology that enhances bioavailability and stability for both large and small molecules. With more than 30 years of experience and several globally approved drugs, the Uppsala‑based firm is developing a diversified clinical and preclinical pipeline in partnership-driven research, development and commercialization, and is listed on Nasdaq Stockholm with ADRs traded on the U.S. OTCQX market.

Average Trading Volume: 72,024

Technical Sentiment Signal: Buy

Current Market Cap: SEK1.02B

Learn more about ORX stock on TipRanks’ Stock Analysis page.